The Company had the following related party transactions during the three and six months ended October 31, 2017 and 2016, respectively.

The Company owns 14.5% of the equity in SG Austria and is reported on the cost method of accounting. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand Co., Ltd. The Company purchased products from these subsidiaries in the approximate amounts of $426,000 and $95,000 in the three months ended October 31, 2017 and 2016, respectively, and approximately $642,000 and $145,000 in the six months ended October 31, 2017 and 2016, respectively.

In April 2014, the Company entered a consulting agreement with Vin-de-Bona Trading Private Limited (“Vin-de-Bona”) pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Walter H. Günzburg and Dr. Brian Salmons, both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes. The term of the agreement is for 12 months, automatically renewable for successive 12 month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. The amounts paid for the three months ended October 31, 2017 and 2016 were approximately $12,000 and $14,000 respectively, and approximately $27,000 and $42,000 for the six months ended October 31, 2017 and 2016, respectively. Also, during the six months ended October 31, 2017 and 2016, the Company awarded shares of restricted common stock to Dr. Salmons for services in the amount of 250,000 and 250,000, respectively, and Dr. Günzburg earned 500,000 shares of the Company’s restricted common stock for the six months ended October 31, 2017.

The Cannabis Licensing Agreement resulted in the Company acquiring from Austrianova an exclusive, world-wide license to use the Cell-in-a-Box^® trademark and its associated technology with genetically modified non-stem cell lines which are designed to activate Cannabinoids to develop therapies involving Cannabis. Under the Cannabis Licensing Agreement, the Company was required to pay Austrianova an Upfront Payment of $2.0 million. As of June 30, 2016, the Company had paid Austrianova the entire $2.0 million of the Upfront Payment.